Top

Current Osteoporosis Reports

Published in:

01-02-2020 | Oral Microbiota | Osteoimmunology (M Nakamura and J Lorenzo, Section Editors)

The Interrelationship Between Diabetes, IL-17 and Bone Loss

Authors: Zhen Huang, Xiyan Pei, Dana T. Graves

Published in: Current Osteoporosis Reports | Issue 1/2020

Abstract

Purpose of Review

Diabetes has a detrimental effect on bone, increasing the risk of fracture and formation of osteolytic lesions such as those seen in periodontitis. Several diabetic complications are caused by diabetes-enhanced inflammation. This review examines mechanisms by which IL-17 contributes to diabetes-enhanced periodontitis and other effects of IL-17 on bone.

Recent Findings

IL-17 upregulates anti-bacterial defenses, yet its expression is also linked to a destructive host response in the periodontium. Periodontal disease is caused by bacteria that stimulate an inflammatory response. Diabetes-enhanced IL-17 increases gingival inflammation, which alters the composition of the oral microbiota to increase its pathogenicity. In addition, IL-17 can induce osteoclastogenesis by upregulation of TNF and RANKL in a number of cell types, and IL-17 has differential effects on osteoblasts and their progenitors.

Summary

Increased IL-17 production caused by diabetes alters the pathogenicity of the oral microbiota and can promote periodontal bone resorption.

Miossec P, Kolls JK. Targeting IL-17 and TH17 cells in chronic inflammation. Nat Rev Drug Discov. 2012;11(10):763–76. https://doi.org/10.1038/nrd3794.CrossRefPubMed

Patel DD, Kuchroo VK. Th17 cell pathway in human immunity: lessons from genetics and therapeutic interventions. Immunity. 2015;43(6):1040–51. https://doi.org/10.1016/j.immuni.2015.12.003.CrossRefPubMed

Harrington LE, Hatton RD, Mangan PR, Turner H, Murphy TL, Murphy KM, et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol. 2005;6(11):1123–32. https://doi.org/10.1038/ni1254.CrossRefPubMed

Cua DJ, Tato CM. Innate IL-17-producing cells: the sentinels of the immune system. Nat Rev Immunol. 2010;10(7):479–89. https://doi.org/10.1038/nri2800.CrossRefPubMed

Sutton CE, Mielke LA, Mills KH. IL-17-producing gammadelta T cells and innate lymphoid cells. Eur J Immunol. 2012;42(9):2221–31. https://doi.org/10.1002/eji.201242569.CrossRefPubMed

Hamada S, Umemura M, Shiono T, Tanaka K, Yahagi A, Begum MD, et al. IL-17A produced by gammadelta T cells plays a critical role in innate immunity against listeria monocytogenes infection in the liver. J Immunol. 2008;181(5):3456–63. https://doi.org/10.4049/jimmunol.181.5.3456.CrossRefPubMed

•• Dutzan N, Kajikawa T, Abusleme L, Greenwell-Wild T, Zuazo CE, Ikeuchi T, et al. A dysbiotic microbiome triggers TH17 cells to mediate oral mucosal immunopathology in mice and humans. Sci Transl Med. 2018;10(463). https://doi.org/10.1126/scitranslmed.aat0797Demonstrates that TH17 cells promote periodontal tissue destruction and pharmacological inhibition of TH17 cell differentiation can reduce periodontal bone loss.CrossRefPubMedPubMedCentral

Wilharm A, Tabib Y, Nassar M, Reinhardt A, Mizraji G, Sandrock I, et al. Mutual interplay between IL-17-producing gammadeltaT cells and microbiota orchestrates oral mucosal homeostasis. Proc Natl Acad Sci U S A. 2019;116(7):2652–61. https://doi.org/10.1073/pnas.1818812116.CrossRefPubMedPubMedCentral

Liu S. Structural insights into the interleukin-17 family cytokines and their receptors. Adv Exp Med Biol. 2019;1172:97-117. https://doi.org/10.1007/978-981-13-9367-9_5

10.

Ho AW, Gaffen SL. IL-17RC: a partner in IL-17 signaling and beyond. Semin Immunopathol. 2010;32(1):33-42. https://doi.org/10.1007/s00281-009-0185-0.CrossRefPubMedPubMedCentral

11.

Dutzan N, Abusleme L, Bridgeman H, Greenwell-Wild T, Zangerle-Murray T, Fife ME, et al. On-going mechanical damage from mastication drives homeostatic Th17 cell responses at the oral barrier. Immunity. 2017;46(1):133–47. https://doi.org/10.1016/j.immuni.2016.12.010.CrossRefPubMedPubMedCentral

12.

Tsukasaki M, Komatsu N, Nagashima K, Nitta T, Pluemsakunthai W, Shukunami C, et al. Host defense against oral microbiota by bone-damaging T cells. Nat Commun. 2018;9(1):701. https://doi.org/10.1038/s41467-018-03147-6.CrossRefPubMedPubMedCentral

13.

Awane M, Andres PG, Li DJ, Reinecker HC. NF-kappa B-inducing kinase is a common mediator of IL-17-, TNF-alpha-, and IL-1 beta-induced chemokine promoter activation in intestinal epithelial cells. J Immunol. 1999;162(9):5337-44.

14.

Shalom-Barak T, Quach J, Lotz M. Interleukin-17-induced gene expression in articular chondrocytes is associated with activation of mitogen-activated protein kinases and NF-kappaB. J Biol Chem. 1998;273(42):27467-73. https://doi.org/10.1074/jbc.273.42.27467.CrossRefPubMed

15.

Graves DT, Li J, Cochran DL. Inflammation and uncoupling as mechanisms of periodontal bone loss. J Dent Res. 2011;90(2):143–53. https://doi.org/10.1177/0022034510385236.CrossRefPubMedPubMedCentral

16.

Pacios S, Xiao W, Mattos M, Lim J, Tarapore RS, Alsadun S, et al. Osteoblast lineage cells play an essential role in periodontal bone loss through activation of nuclear factor-kappa B. Sci Rep. 2015;5:16694. https://doi.org/10.1038/srep16694.CrossRefPubMedPubMedCentral

17.

Graves DT, Alshabab A, Albiero ML, Mattos M, Correa JD, Chen S, et al. Osteocytes play an important role in experimental periodontitis in healthy and diabetic mice through expression of RANKL. J Clin Periodontol. 2018;45(3):285–92. https://doi.org/10.1111/jcpe.12851.CrossRefPubMedPubMedCentral

18.

Zheng J, Chen S, Albiero ML, Vieira GHA, Wang J, Feng JQ, et al. Diabetes activates periodontal ligament fibroblasts via NF-kappaB in vivo. J Dent Res. 2018;97(5):580–8. https://doi.org/10.1177/0022034518755697.CrossRefPubMedPubMedCentral

19.

Pacios S, Kang J, Galicia J, Gluck K, Patel H, Ovaydi-Mandel A, et al. Diabetes aggravates periodontitis by limiting repair through enhanced inflammation. FASEB J. 2012;26(4):1423–30. https://doi.org/10.1096/fj.11-196279.CrossRefPubMedPubMedCentral

20.

Zenobia C, Hajishengallis G. Basic biology and role of interleukin-17 in immunity and inflammation. Periodontol 2000. 2015;69(1):142–59. https://doi.org/10.1111/prd.12083.CrossRefPubMedPubMedCentral

21.

Johnson RB, Wood N, Serio FG. Interleukin-11 and IL-17 and the pathogenesis of periodontal disease. J Periodontol. 2004;75(1):37–43. https://doi.org/10.1902/jop.2004.75.1.37.CrossRefPubMed

22.

Chen XT, Chen LL, Tan JY, Shi DH, Ke T, Lei LH. Th17 and Th1 Lymphocytes Are Correlated with Chronic Periodontitis. Immunol Invest. 2016;45(3):243-54. https://doi.org/10.3109/08820139.2016.1138967.CrossRefPubMed

23.

Dutzan N, Vernal R, Vaque JP, Garcia-Sesnich J, Hernandez M, Abusleme L, et al. Interleukin-21 expression and its association with proinflammatory cytokines in untreated chronic periodontitis patients. J Periodontol. 2012;83(7):948–54. https://doi.org/10.1902/jop.2011.110482.CrossRefPubMed

24.

Lester SR, Bain JL, Johnson RB, Serio FG. Gingival concentrations of interleukin-23 and -17 at healthy sites and at sites of clinical attachment loss. J Periodontol. 2007;78(8):1545–50. https://doi.org/10.1902/jop.2007.060458.CrossRefPubMed

25.

Yu JJ, Ruddy MJ, Wong GC, Sfintescu C, Baker PJ, Smith JB, et al. An essential role for IL-17 in preventing pathogen-initiated bone destruction: recruitment of neutrophils to inflamed bone requires IL-17 receptor-dependent signals. Blood. 2007;109(9):3794–802. https://doi.org/10.1182/blood-2005-09-010116.CrossRefPubMedPubMedCentral

26.

Eskan MA, Jotwani R, Abe T, Chmelar J, Lim JH, Liang S, et al. The leukocyte integrin antagonist Del-1 inhibits IL-17-mediated inflammatory bone loss. Nat Immunol. 2012;13(5):465–73. https://doi.org/10.1038/ni.2260.CrossRefPubMedPubMedCentral

27.

Wu Y, Dong G, Xiao W, Xiao E, Miao F, Syverson A, et al. Effect of aging on periodontal inflammation, microbial colonization, and disease susceptibility. J Dent Res. 2016;95(4):460–6. https://doi.org/10.1177/0022034515625962.CrossRefPubMedPubMedCentral

28.

IDF Diabetes Atlas. 8th ed. Brussels, Belgium: International Diabetes Federation; 2017.

29.

Sami W, Ansari T, Butt NS, Hamid MRA. Effect of diet on type 2 diabetes mellitus: a review. Int J Health Sci (Qassim). 2017;11(2):65–71.

30.

Boldison J, Wong FS. Immune and pancreatic beta cell interactions in type 1 diabetes. Trends Endocrinol Metab. 2016;27(12):856–67. https://doi.org/10.1016/j.tem.2016.08.007.CrossRefPubMed

31.

Xiao E, Wu Y, Graves DT. Impact of diabetes on periodontal disease. In: Diabetic bone disease: Springer; 2016. p. 95–112.CrossRef

32.

Nelson RG, Shlossman M, Budding LM, Pettitt DJ, Saad MF, Genco RJ, et al. Periodontal disease and NIDDM in Pima Indians. Diabetes Care. 1990;13(8):836–40. https://doi.org/10.2337/diacare.13.8.836.CrossRefPubMed

33.

Novotna M, Podzimek S, Broukal Z, Lencova E, Duskova J. Periodontal diseases and dental caries in children with type 1 diabetes mellitus. Mediat Inflamm. 2015;2015:379626. https://doi.org/10.1155/2015/379626.CrossRef

34.

Shlossman M, Knowler WC, Pettitt DJ, Genco RJ. Type 2 diabetes mellitus and periodontal disease. J Am Dent Assoc. 1990;121(4):532–6. https://doi.org/10.14219/jada.archive.1990.0211.CrossRefPubMed

35.

• Graves DT, Corrêa JD, Silva TA. The Oral Microbiota Is Modified by Systemic Diseases. J Dent Res. 2019;98:148-156. https://doi.org/10.1177/0022034518805739. This review discusses the oral microbiome and how it is modified by systemic diseases such as diabetes, rheumatoid arthritis and lupus erythematosus.CrossRefPubMedPubMedCentral

36.

Taylor G, Burt B, Becker M, Genco R, Shlossman M, Knowler W, et al. Non-insulin dependent diabetes mellitus and alveolar bone loss progression over 2 years. J Periodontol. 1998;69:76–83. https://doi.org/10.1902/jop.1998.69.1.76.CrossRefPubMed

37.

Safkan-Seppala B, Sorsa T, Tervahartiala T, Beklen A, Konttinen YT. Collagenases in gingival crevicular fluid in type 1 diabetes mellitus. J Periodontol. 2006;77(2):189-94. https://doi.org/10.1902/jop.2006.040322.CrossRefPubMed

38.

Patil VS, Patil VP, Gokhale N, Acharya A, Kangokar P. Chronic periodontitis in type 2 diabetes mellitus: oxidative stress as a common factor in periodontal tissue injury. J Clin Diagn Res. 2016;10(4):Bc12–6. https://doi.org/10.7860/jcdr/2016/17350.7542.CrossRefPubMedPubMedCentral

39.

Albert DA, Ward A, Allweiss P, Graves DT, Knowler WC, Kunzel C et al. Diabetes and oral disease: implications for health professionals. Ann N Y Acad Sci. 2012;1255:1-15. https://doi.org/10.1111/j.1749-6632.2011.06460.x.CrossRefPubMedPubMedCentral

40.

Karima M, Kantarci A, Ohira T, Hasturk H, Jones VL, Nam BH, et al. Enhanced superoxide release and elevated protein kinase C activity in neutrophils from diabetic patients: association with periodontitis. J Leukoc Biol. 2005;78(4):862–70. https://doi.org/10.1189/jlb.1004583.CrossRefPubMed

41.

Salvi GE, Beck JD, Offenbacher S. PGE2, IL-1 beta, and TNF-alpha responses in diabetics as modifiers of periodontal disease expression. Ann Periodontol. 1998;3(1):40–50. https://doi.org/10.1902/annals.1998.3.1.40.CrossRefPubMed

42.

Song L, Dong G, Guo L, Graves DT. The function of dendritic cells in modulating the host response. Mol Oral Microbiol. 2018;33(1):13–21. https://doi.org/10.1111/omi.12195.CrossRefPubMed

43.

Kim JH, Lee DE, Choi SH, Cha JH, Bak EJ, Yoo YJ. Diabetic characteristics and alveolar bone loss in streptozotocin- and streptozotocin-nicotinamide-treated rats with periodontitis. J Periodontal Res. 2014;49(6):792–800. https://doi.org/10.1111/jre.12165.CrossRefPubMed

44.

Wu YY, Xiao E, Graves DT. Diabetes mellitus related bone metabolism and periodontal disease. Int J Oral Sci. 2015;7(2):63-72. https://doi.org/10.1038/ijos.2015.2.CrossRefPubMedPubMedCentral

45.

Lalla E, Lamster IB, Feit M, Huang L, Spessot A, Qu W, et al. Blockade of RAGE suppresses periodontitis-associated bone loss in diabetic mice. J Clin Invest. 2000;105(8):1117–24. https://doi.org/10.1172/JCI8942.CrossRefPubMedPubMedCentral

46.

Pacios S, Andriankaja O, Kang J, Alnammary M, Bae J, de Brito BB, et al. Bacterial infection increases periodontal bone loss in diabetic rats through enhanced apoptosis. Am J Pathol. 2013;183(6):1928–35. https://doi.org/10.1016/j.ajpath.2013.08.017.CrossRefPubMedPubMedCentral

47.

• Napoli N, Chandran M, Pierroz DD, Abrahamsen B, Schwartz AV, Ferrari SL, et al. Mechanisms of diabetes mellitus-induced bone fragility. Nat Rev Endocrinol. 2017;13(4):208–19. https://doi.org/10.1038/nrendo.2016.153This review discusses how conditions present in diabetes, increased inflammation, hyperglycaemia, oxidative stress and advanced glycation endproducts affect bone formation and resorption in type-1 and type-2 diabetes. CrossRefPubMed

48.

Jiao H, Xiao E, Graves DT. Diabetes and Its Effect on Bone and Fracture Healing. Curr Osteoporos Rep. 2015;13(5):327-35. https://doi.org/10.1007/s11914-015-0286-8 CrossRefPubMedPubMedCentral

49.

Lu H, Kraut D, Gerstenfeld LC, Graves DT. Diabetes interferes 559 with the bone formation by affecting the expression of transcrip- 560 tion factors that regulate osteoblast differentiation. Endocrinology. 5612003;144(1):346–52. https://doi.org/10.1210/en.2002-220072.CrossRefPubMed

50.

Liu R, Bal H, Desta T, Krothapalli N, Alyassi M, Luan Q, et al. Diabetes enhances periodontal bone loss through enhanced resorption and diminished bone formation. J Dent Res. 2006;85(6):510–4. https://doi.org/10.1177/154405910608500606.CrossRefPubMed

51.

Ko KI, Coimbra LS, Tian C, Alblowi J, Kayal RA, Einhorn TA, et al. Diabetes reduces mesenchymal stem cells in fracture healing through a TNFalpha-mediated mechanism. Diabetologia. 2015;58(3):633–42. https://doi.org/10.1007/s00125-014-3470-y.CrossRefPubMedPubMedCentral

52.

Lim JC, Ko KI, Mattos M, Fang M, Zhang C, Feinberg D, et al. TNFalpha contributes to diabetes impaired angiogenesis in fracture healing. Bone. 2017;99:26–38. https://doi.org/10.1016/j.bone.2017.02.014.CrossRefPubMedPubMedCentral

53.

Liu J, Jiang Y, Mao J, Gu B, Liu H, Fang B. High levels of glucose induces a dose-dependent apoptosis in human periodontal ligament fibroblasts by activating caspase-3 signaling pathway. Appl Biochem Biotechnol. 2013;170(6):1458–71. https://doi.org/10.1007/s12010-013-0287-y.CrossRefPubMed

54.

Behl Y, Krothapalli P, Desta T, Roy S, Graves DT. FOXO1 plays an important role in enhanced microvascular cell apoptosis and microvascular cell loss in type 1 and type 2 diabetic rats. Diabetes. 2009;58(4):917-25. https://doi.org/10.2337/db08-0537.CrossRefPubMedPubMedCentral

55.

Weinberg E, Maymon T, Moses O, Weinreb M. Streptozotocin-induced diabetes in rats diminishes the size of the osteoprogenitor pool in bone marrow. Diabetes Res Clin Pract. 2014;103(1):35–41. https://doi.org/10.1016/j.diabres.2013.11.015.CrossRefPubMed

56.

Kanazawa I, Sugimoto T. Diabetes mellitus-induced bone fragility. Intern Med. 2018;57(19):2773–85. https://doi.org/10.2169/internalmedicine.0905-18.CrossRefPubMedPubMedCentral

57.

Li DX, Deng TZ, Lv J, Ke J. Advanced glycation end products (AGEs) and their receptor (RAGE) induce apoptosis of periodontal ligament fibroblasts. Braz J Med Biol Res. 2014;47(12):1036–43.CrossRefPubMedPubMedCentral

58.

Al-Mashat HA, Kandru S, Liu R, Behl Y, Desta T, Graves DT. Diabetes enhances mRNA levels of proapoptotic genes and caspase activity, which contribute to impaired healing. Diabetes. 2006;55(2):487–95. https://doi.org/10.2337/diabetes.55.02.06.db05-1201.CrossRefPubMed

59.

Cianciola LJ, Park BH, Bruck E, Mosovich L, Genco RJ. Prevalence of periodontal disease in insulin-dependent diabetes mellitus (juvenile diabetes). J Am Dent Assoc. 1982;104(5):653–60. https://doi.org/10.14219/jada.archive.1982.0240.CrossRefPubMed

60.

Andriankaja OM, Galicia J, Dong G, Xiao W, Alawi F, Graves DT. Gene expression dynamics during diabetic periodontitis. J Dent Res. 2012;91(12):1160–5. https://doi.org/10.1177/0022034512465292.CrossRefPubMedPubMedCentral

61.

Lalla E, Papapanou PN. Diabetes mellitus and periodontitis: a tale of two common interrelated diseases. Nat Rev Endocrinol. 2011;7(12):738–48. https://doi.org/10.1038/nrendo.2011.106.CrossRefPubMed

62.

Loe H. Periodontal disease. The sixth complication of diabetes mellitus. Diabetes Care. 1993;16(1):329–34.CrossRefPubMed

63.

Casarin RC, Barbagallo A, Meulman T, Santos VR, Sallum EA, Nociti FH, et al. Subgingival biodiversity in subjects with uncontrolled type-2 diabetes and chronic periodontitis. J Periodontal Res. 2013;48(1):30–6. https://doi.org/10.1111/j.1600-0765.2012.01498.x.CrossRefPubMed

64.

Mashimo PA, Yamamoto Y, Slots J, Park BH, Genco RJ. The periodontal microflora of juvenile diabetics. Culture, immunofluorescence, and serum antibody studies. J Periodontol. 1983;54(7):420–30. https://doi.org/10.1902/jop.1983.54.7.420.CrossRefPubMed

65.

Campus G, Salem A, Uzzau S, Baldoni E, Tonolo G. Diabetes and periodontal disease: a case-control study. J Periodontol. 2005;76(3):418–25. https://doi.org/10.1902/jop.2005.76.3.418.CrossRefPubMed

66.

da Cruz GA, de Toledo S, Sallum EA, Sallum AW, Ambrosano GM, de Cassia Orlandi Sardi J, et al. Clinical and laboratory evaluations of non-surgical periodontal treatment in subjects with diabetes mellitus. J Periodontol. 2008;79(7):1150–7. https://doi.org/10.1902/jop.2008.070503.CrossRefPubMed

67.

Sastrowijoto SH, Hillemans P, van Steenbergen TJ, Abraham-Inpijn L, de Graaff J. Periodontal condition and microbiology of healthy and diseased periodontal pockets in type 1 diabetes mellitus patients. J Clin Periodontol. 1989;16(5):316–22. https://doi.org/10.1111/j.1600-051x.1989.tb01662.x.CrossRefPubMed

68.

Aemaimanan P, Amimanan P, Taweechaisupapong S. Quantification of key periodontal pathogens in insulin-dependent type 2 diabetic and non-diabetic patients with generalized chronic periodontitis. Anaerobe. 2013;22:64–8. https://doi.org/10.1016/j.anaerobe.2013.06.010.CrossRefPubMed

69.

Demmer RT, Breskin A, Rosenbaum M, Zuk A, LeDuc C, Leibel R, et al. The subgingival microbiome, systemic inflammation and insulin resistance: the oral infections, glucose intolerance and insulin resistance study. J Clin Periodontol. 2017;44(3):255–65. https://doi.org/10.1111/jcpe.12664.CrossRefPubMedPubMedCentral

70.

Merchant AT, Shrestha D, Chaisson C, Choi YH, Hazlett LJ, Zhang J. Association between serum antibodies to oral microorganisms and hyperglycemia in adults. J Dent Res. 2014;93(8):752–9. https://doi.org/10.1177/0022034514538451.CrossRefPubMedPubMedCentral

71.

Sakalauskiene J, Kubilius R, Gleiznys A, Vitkauskiene A, Ivanauskiene E, Saferis V. Relationship of clinical and microbiological variables in patients with type 1 diabetes mellitus and periodontitis. Med Sci Monit. 2014;20:1871–7. https://doi.org/10.12659/MSM.890879.CrossRefPubMedPubMedCentral

72.

Zhou M, Rong R, Munro D, Zhu C, Gao X, Zhang Q, et al. Investigation of the effect of type 2 diabetes mellitus on subgingival plaque microbiota by high-throughput 16S rDNA pyrosequencing. PLoS One. 2013;8(4):e61516. https://doi.org/10.1371/journal.pone.0061516.CrossRefPubMedPubMedCentral

73.

Graves DT, Naguib G, Lu H, Leone C, Hsue H, Krall E. Inflammation is more persistent in type 1 diabetic mice. J Dent Res. 2005;84:324–8.CrossRefPubMed

74.

Naguib G, Al-Mashat H, Desta T, Graves DT. Diabetes prolongs the inflammatory response to a bacterial stimulus through cytokine dysregulation. J Invest Dermatol. 2004;123:87–92. https://doi.org/10.1111/j.0022-202X.2004.22711.x.CrossRefPubMed

75.

•• Xiao E, Mattos M, Vieira GHA, Chen S, Correa JD, Wu Y, et al. Diabetes enhances IL-17 expression and alters the oral microbiome to increase its pathogenicity. Cell Host Microbe. 2017;22(1):120–8 e4. https://doi.org/10.1016/j.chom.2017.06.014This study shows that IL-17 alters the oral bacterial composition in diabetic mice and that the oral bacteria from diabetic mice are more pathogenic when transferred to germ free hosts than bacteria from normoglycemic controls. The increased pathogencity of oral bacteria in diabetic mice is largely reversed by inhibiton of IL-17. CrossRefPubMedPubMedCentral

76.

Grice EA, Snitkin ES, Yockey LJ, Bermudez DM, Program NCS, Liechty KW, et al. Longitudinal shift in diabetic wound microbiota correlates with prolonged skin defense response. Proc Natl Acad Sci U S A. 2010;107(33):14799–804. https://doi.org/10.1073/pnas.1004204107.CrossRefPubMedPubMedCentral

77.

Patterson E, Marques TM, O’Sullivan O, Fitzgerald P, Fitzgerald GF, Cotter PD, et al. Streptozotocin-induced type-1-diabetes disease onset in Sprague-Dawley rats is associated with an altered intestinal microbiota composition and decreased diversity. Microbiology. 2015;161(Pt 1):182–93. https://doi.org/10.1099/mic.0.082610-0 CrossRefPubMed

78.

Ussar S, Fujisaka S, Kahn CR. Interactions between host genetics and gut microbiome in diabetes and metabolic syndrome. Mol Metab. 2016;5(9):795–803. https://doi.org/10.1016/j.molmet.2016.07.004.CrossRefPubMedPubMedCentral

79.

Curtis MA, Zenobia C, Darveau RP. The relationship of the oral microbiotia to periodontal health and disease. Cell Host Microbe. 2011;10(4):302–6. https://doi.org/10.1016/j.chom.2011.09.008.CrossRefPubMedPubMedCentral

80.

Abusleme L, Moutsopoulos NM. IL-17: overview and role in oral immunity and microbiome. Oral Dis. 2017;23(7):854–65. https://doi.org/10.1111/odi.12598.CrossRefPubMed

81.

Won HY, Lee JA, Park ZS, Song JS, Kim HY, Jang SM, et al. Prominent bone loss mediated by RANKL and IL-17 produced by CD4+ T cells in TallyHo/JngJ mice. PLoS One. 2011;6(3):e18168. https://doi.org/10.1371/journal.pone.0018168.CrossRefPubMedPubMedCentral

82.

Zhao R, Wang X, Feng F. Upregulated cellular expression of IL-17 by CD4+ T-cells in osteoporotic postmenopausal women. Ann Nutr Metab. 2016;68(2):113–8. https://doi.org/10.1159/000443531.CrossRefPubMed

83.

Tyagi AM, Srivastava K, Mansoori MN, Trivedi R, Chattopadhyay N, Singh D. Estrogen deficiency induces the differentiation of IL-17 secreting Th17 cells: a new candidate in the pathogenesis of osteoporosis. PLoS One. 2012;7(9):e44552. https://doi.org/10.1371/journal.pone.0044552.CrossRefPubMedPubMedCentral

84.

DeSelm CJ, Takahata Y, Warren J, Chappel JC, Khan T, Li X, et al. IL-17 mediates estrogen-deficient osteoporosis in an Act1-dependent manner. J Cell Biochem. 2012;113(9):2895–902. https://doi.org/10.1002/jcb.24165.CrossRefPubMedPubMedCentral

85.

Tyagi AM, Mansoori MN, Srivastava K, Khan MP, Kureel J, Dixit M, et al. Enhanced immunoprotective effects by anti-IL-17 antibody translates to improved skeletal parameters under estrogen deficiency compared with anti-RANKL and anti-TNF-alpha antibodies. J Bone Miner Res. 2014;29(9):1981–92. https://doi.org/10.1002/jbmr.2228.CrossRefPubMed

86.

Shukla P, Mansoori MN, Singh D. Efficacy of anti-IL-23 monotherapy versus combination therapy with anti-IL-17 in estrogen deficiency induced bone loss conditions. Bone. 2018;110:84–95. https://doi.org/10.1016/j.bone.2018.01.027.CrossRefPubMed

87.

Uluckan O, Jimenez M, Karbach S, Jeschke A, Grana O, Keller J, et al. Chronic skin inflammation leads to bone loss by IL-17-mediated inhibition of Wnt signaling in osteoblasts. Sci Transl Med. 2016;8(330):330ra37. https://doi.org/10.1126/scitranslmed.aad8996.CrossRefPubMed

88.

Ono T, Takayanagi H. Osteoimmunology in bone fracture healing. Curr Osteoporos Rep. 2017;15(4):367–75. https://doi.org/10.1007/s11914-017-0381-0.CrossRefPubMed

89.

Ono T, Okamoto K, Nakashima T, Nitta T, Hori S, Iwakura Y, et al. IL-17-producing gammadelta T cells enhance bone regeneration. Nat Commun. 2016;7:10928. https://doi.org/10.1038/ncomms10928.CrossRefPubMedPubMedCentral

90.

Bahney CS, Zondervan RL, Allison P, Theologis A, Ashley JW, Ahn J, et al. Cellular biology of fracture healing. J Orthop Res. 2019;37(1):35–50. https://doi.org/10.1002/jor.24170.CrossRefPubMed

91.

Croes M, Kruyt MC, Groen WM, van Dorenmalen KMA, Dhert WJA, Oner FC, et al. Interleukin 17 enhances bone morphogenetic protein-2-induced ectopic bone formation. Sci Rep. 2018;8(1):7269. https://doi.org/10.1038/s41598-018-25564-9.CrossRefPubMedPubMedCentral

92.

Lubberts E, van den Bersselaar L, Oppers-Walgreen B, Schwarzenberger P, Coenen-de Roo CJ, Kolls JK, et al. IL-17 promotes bone erosion in murine collagen-induced arthritis through loss of the receptor activator of NF-kappa B ligand/osteoprotegerin balance. J Immunol. 2003;170(5):2655–62. https://doi.org/10.4049/jimmunol.170.5.2655.CrossRefPubMed

93.

Reynolds G, Cooles FA, Isaacs JD, Hilkens CM. Emerging immunotherapies for rheumatoid arthritis. Hum Vaccin Immunother. 2014;10(4):822–37. https://doi.org/10.4161/hv.27910.CrossRefPubMedPubMedCentral

94.

Li X, Yuan FL, Lu WG, Zhao YQ, Li CW, Li JP, et al. The role of interleukin-17 in mediating joint destruction in rheumatoid arthritis. Biochem Biophys Res Commun. 2010;397(2):131–5. https://doi.org/10.1016/j.bbrc.2010.05.111.CrossRefPubMed

95.

Koenders MI, Lubberts E, Oppers-Walgreen B, van den Bersselaar L, Helsen MM, Di Padova FE, et al. Blocking of interleukin-17 during reactivation of experimental arthritis prevents joint inflammation and bone erosion by decreasing RANKL and interleukin-1. Am J Pathol. 2005;167(1):141–9. https://doi.org/10.1016/S0002-9440(10)62961-6.CrossRefPubMedPubMedCentral

96.

Karmakar S, Kay J, Gravallese EM. Bone damage in rheumatoid arthritis: mechanistic insights and approaches to prevention. Rheum Dis Clin N Am. 2010;36(2):385–404. https://doi.org/10.1016/j.rdc.2010.03.003.CrossRef

97.

van den Berg WB, Miossec P. IL-17 as a future therapeutic target for rheumatoid arthritis. Nat Rev Rheumatol. 2009;5(10):549–53. https://doi.org/10.1038/nrrheum.2009.179.CrossRefPubMed

98.

Daoussis D, Andonopoulos AP, Liossis SN. Wnt pathway and IL-17: novel regulators of joint remodeling in rheumatic diseases. Looking beyond the RANK-RANKL-OPG axis. Semin Arthritis Rheum. 2010;39(5):369–83. https://doi.org/10.1016/j.semarthrit.2008.10.008.CrossRefPubMed

99.

Kampylafka E, d’Oliveira I, Linz C, Lerchen V, Stemmler F, Simon D, et al. Resolution of synovitis and arrest of catabolic and anabolic bone changes in patients with psoriatic arthritis by IL-17A blockade with secukinumab: results from the prospective PSARTROS study. Arthritis Res Ther. 2018;20(1):153. https://doi.org/10.1186/s13075-018-1653-5.CrossRefPubMedPubMedCentral

100.

van der Heijde D, Gladman DD, Kishimoto M, Okada M, Rathmann SS, Moriarty SR, et al. Efficacy and safety of ixekizumab in patients with active psoriatic arthritis: 52-week results from a phase III study (SPIRIT-P1). J Rheumatol. 2018;45(3):367–77. https://doi.org/10.3899/jrheum.170429.CrossRefPubMed

101.

Blanco FJ, Moricke R, Dokoupilova E, Codding C, Neal J, Andersson M, et al. Secukinumab in active rheumatoid arthritis: a phase III randomized, double-blind, active comparator- and placebo-controlled study. Arthritis Rheumatol. 2017;69(6):1144–53. https://doi.org/10.1002/art.40070.CrossRefPubMed

Title: The Interrelationship Between Diabetes, IL-17 and Bone Loss
Authors: Zhen Huang
Xiyan Pei
Dana T. Graves
Publication date: 01-02-2020
Publisher: Springer US
Keywords: Oral Microbiota
Gingival Diseases
Cytokines
Published in: Current Osteoporosis Reports / Issue 1/2020
Print ISSN: 1544-1873
Electronic ISSN: 1544-2241
DOI: https://doi.org/10.1007/s11914-020-00559-6

Keynote webinar | Spotlight on medication adherence

Springer Medicine

The Interrelationship Between Diabetes, IL-17 and Bone Loss

Abstract

Purpose of Review

Recent Findings

Summary

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 1/2020

Spaceflight-Induced Bone Tissue Changes that Affect Bone Quality and Increase Fracture Risk

Complicated Muscle-Bone Interactions in Children with Cerebral Palsy

The Effects of Sclerostin on the Immune System

MRI Assessment of Bone Marrow Composition in Osteoporosis

Osteocyte-Mediated Translation of Mechanical Stimuli to Cellular Signaling and Its Role in Bone and Non-bone-Related Clinical Complications

General and Specific Considerations as to why Osteoporosis-Related Care Is Often Suboptimal